Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dose-finding trial of oral GW117 for depression
CTR20221222Phase 2Completed
- Sponsor
- Guangwei Pharmaceutical
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GW117 in major depressive disorder (MDD), sponsored by Guangwei Pharmaceutical. Started May 2022; status: completed.
02
Drugs
GW117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20221222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221222.